var data={"title":"Bezafibrate (United States: Not available): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bezafibrate (United States: Not available): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5739?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bezafibrate-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bezafibrate (United States: Not available): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141141\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Bezalip SR;</li>\n      <li>JAMP-Bezafibrate SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141181\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antilipemic Agent, Fibric Acid</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141145\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Dyslipidemia:</b> Oral: 400 mg once daily </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990027\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &ge;60 mL/minute: No dosage adjustment required</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">CrCl &lt;60 mL/minute <b>or</b> S<sub>cr</sub> &gt;1.5 mg/dL [&gt;135 micromol/L]: Use is contraindicated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dialysis: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987311\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12617470\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dyslipidemia:</b> Children and Adolescents: Oral: 10 to 20 mg/kg/day (maximum: 400 mg daily). <b>Note:</b> Limited experience available; use caution. Based on child&rsquo;s weight, dosing may not be possible as the manufacturer recommends administering the sustained release tablet whole.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2649926\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dyslipidemia:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &le;70 years: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients &gt;70 years: Avoid use in patients &gt;70 years due to declining renal function and the likelihood of CrCl &lt;60 mL/minute in this population. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10076205\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, sustained release, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bezalip SR: 400 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11217333\" class=\"block prod-avail drugH1Div\"><span class=\"drugH1\">Product Availability</span>\n    <p style=\"text-indent:0em;display:inline\">Not available in the US</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141120\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Do not crush or chew tablet; should be swallowed whole with sufficient fluid. Administer in morning or evening with or after meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141119\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Not approved in the US</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dyslipidemia:</b> Adjunct to diet and other therapeutic measures for treatment of type IIa and IIb mixed hyperlipidemia, to regulate lipid and apoprotein levels (reduce serum TG, LDL-cholesterol, and apolipoprotein B, increase HDL-cholesterol and apolipoprotein A); treatment of adult patients with high to very high triglyceride levels (Fredrickson classification type IV and V hyperlipidemias) who are at high risk of sequelae and complications from their dyslipidemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141108\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Headache (4%), dizziness (2%), insomnia (1%), migraine (1%), pain (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus (3%), eczema (1%), erythema, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Gastritis (6%), flatulence (5%), dyspepsia (3%), constipation, diarrhea, epigastric distress, nausea </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT, increased serum AST </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Increased creatine phosphokinase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchitis, pharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Acute renal failure, alopecia, cholelithiasis, decreased gamma-glutamyl transferase, decreased platelet count, decreased serum alkaline phosphatase, decreased white blood cell count, erectile dysfunction, immune thrombocytopenia, increased serum alkaline phosphatase, increased serum creatinine, muscle cramps, myalgia, myopathy, pancytopenia, rhabdomyolysis, skin photosensitivity, Stevens-Johnson syndrome, toxic epidermal necrolysis, weakness </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141123\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to bezafibrate, fibrates, or any component of the formulation; photoallergic or phototoxic reactions to fibrates; hepatic impairment; primary biliary cirrhosis; renal impairment (serum creatinine &gt;1.5 mg/dL [&gt;135 micromol/L], CrCl &lt;60 mL/minute, or patients undergoing dialysis); pre-existing gallbladder disease; concomitant use with HMG CoA reductase inhibitors in patients predisposed to myopathy (eg, preexisting renal impairment, hormonal or electrolyte imbalance, severe infection, trauma, surgery); pregnancy or breast-feeding; not indicated for the treatment of type I hyperlipoproteinemia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141106\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hematologic effects: Mild decreases in WBCs, platelets, and hemoglobin may occur following initiation of therapy; levels tend to stabilize with prolonged therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic effects: Has been shown to be hepatotoxic; discontinue therapy if significant response is not obtained in 3 months. Use with caution in patients with history of jaundice or hepatic disorder. Abnormal liver function tests have been observed; discontinue therapy if abnormalities persist (reversible when discontinued). May increase risk for cholelithiasis; discontinue therapy in patients diagnosed with cholelithiasis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myopathy/rhabdomyolysis: Has been associated with rare myositis or rhabdomyolysis (usually with renal impairment); monitor closely. Instruct patients to report unexplained muscle pain, tenderness, weakness, or brown urine. Evaluate creatine phosphokinase (CPK) levels with signs/symptoms of myotoxicity; discontinue therapy with marked elevation of CPK (10 x ULN) or diagnosis of myopathy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Due to the likelihood of renal impairment (CrCl &lt;60 mL/minute) in patients &gt;70 years of age, use is not recommended in this patient population.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pediatric: Limited experience is available in children; therefore, caution should be used when treating children. Accurate dosing may not be achievable as sustained release tablet should be administered whole and not cut.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141177\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141110\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8696&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Fibric Acid Derivatives. Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.<b> Exceptions: </b>Colesevelam.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chenodiol: Fibric Acid Derivatives may diminish the therapeutic effect of Chenodiol.  Management: Monitor clinical response to chenodiol closely when used together with any fibric acid derivative.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofibrate: May enhance the adverse/toxic effect of Fibric Acid Derivatives.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic). Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ezetimibe: Bezafibrate may enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Bezafibrate may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin  Management: Monitor patients closely for myopathy with concomitant use of bezafibrate and HMG-CoA reductase inhibitors. Concomitant use is contraindicated in patients predisposed to myopathy and alternative therapy should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mizoribine: May enhance the adverse/toxic effect of Bezafibrate. Specifically, the risk for muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Bezafibrate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Fibric Acid Derivatives may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ursodiol: Fibric Acid Derivatives may diminish the therapeutic effect of Ursodiol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Fibric Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141126\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Use is contraindicated in pregnant women. Therapy should be discontinued in women who become pregnant during therapy. Women planning pregnancy should discontinue bezafibrate several months before conception and women of childbearing potential should use effective birth control methods.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141127\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if bezafibrate is excreted in breast milk. Use in breast-feeding women is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141128\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Before initiation of therapy, patients should be placed on a standard lipid-lowering diet for 6 weeks and the diet should be continued during drug therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141115\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic evaluation of serum lipids, cholesterol, and triglycerides (especially in the first few months of therapy). LFTs after 3-6 months; then at least annually. CBC (periodically during the first 12 months). Fasting glucose, creatinine, and CPK periodically.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141105\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Mechanism not definitely established; may increase VLDL catabolism by increasing lipoprotein and hepatic triglyceride lipase activities; attenuation of triglyceride biosynthesis by inhibition of acetyl-CoA carboxylase; decreased cholesterol biosynthesis by inhibition of 3-hydroxy-3-methyglutaryl-coenzyme A reductase</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141122\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: ~17 L </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 94% to 96% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 1-2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: 3-4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (95%); feces (3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141129\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Befibrat (DE);</li>\n      <li>Befizal (FR);</li>\n      <li>Bezacur (LU);</li>\n      <li>Bezafibrat (DE, DK);</li>\n      <li>Bezalip (AE, AR, AT, BH, CY, CZ, EG, FI, GB, GR, HK, HN, HU, ID, IE, IN, IT, JO, JP, KW, MT, MX, NL, NZ, PK, PT, QA, SA, SE, TH, TW, VE, ZA);</li>\n      <li>Bezalip PR (TR);</li>\n      <li>Bezalip Retard (BH, EC, HK, ID, IN, KR, KW, MX, NL, NZ, PE, PT, QA, SA, TW, UY);</li>\n      <li>Bezalip Rwetard (AE);</li>\n      <li>Bezamidin (CZ, HR, HU, PL);</li>\n      <li>Bezamil (TH);</li>\n      <li>Bezastad (PH);</li>\n      <li>Bezatol SR (JP);</li>\n      <li>Cedur (BE, BR, DE, LU);</li>\n      <li>Cedur Retard (CH);</li>\n      <li>Clofibral (PY);</li>\n      <li>Decrilip (ID);</li>\n      <li>Difaterol (ES);</li>\n      <li>Elpilip (AR);</li>\n      <li>Etifibrat (SV);</li>\n      <li>Eulip (TW);</li>\n      <li>Eulitop (BE, ES);</li>\n      <li>Lacromid (CY, TR);</li>\n      <li>Lipitrol (QA);</li>\n      <li>Lipocin (MX);</li>\n      <li>Lipocor (PK);</li>\n      <li>Nimus (CL);</li>\n      <li>Norlip (IL);</li>\n      <li>Oralipin (CL);</li>\n      <li>Oralipin Retard (PY);</li>\n      <li>Polyzalip (TH);</li>\n      <li>Regadrin B (VN);</li>\n      <li>Zafibral (JO, SG);</li>\n      <li>Zafular (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bezalip SR (bezafibrate) [Canadian product monograph]. Hafnarfjordur, Iceland: ACTAVIS Group PTC ehf; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ericsson CG, Nilsson J, Grip L, et al, &ldquo;Effect of Bezafibrate Treatment Over Five Years on Coronary Plaques Causing 20% to 50% Diameter Narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]),&rdquo; <i>Am J Cardiol</i>, 1997, 80(9):1125-9. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/9359536/pubmed\" target=\"_blank\" id=\"9359536\">9359536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III),&rdquo; <i>JAMA</i>, 2001, 285(19):2486-97. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/11368702/pubmed\" target=\"_blank\" id=\"11368702\">11368702</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Genest J, McPherson R, Frohlich J, et al, &ldquo;2009 Canadian Cardiovascular Society/Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease in the Adult &ndash; 2009 Recommendations,&rdquo; <i>Can J Cardiol</i>, 2009, 25(10):567-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/19812802/pubmed\" target=\"_blank\" id=\"19812802\">19812802</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McPherson R, Frohlich J, Fodor G, et al, &ldquo;Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease,&rdquo; [published correction appears in <i>Can J Cardiol</i>. 2006;22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/16971976/pubmed\" target=\"_blank\" id=\"16971976\">16971976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study. The BIP Study Group,&rdquo; <i>Circulation</i>, 2000, 102(1):21-7<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/10880410/pubmed\" target=\"_blank\" id=\"10880410\">10880410</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8696 Version 94.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F141141\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F141181\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F141145\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990027\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987311\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F12617470\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2649926\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F10076205\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Product Availability\" href=\"#F11217333\" class=\"outlineLink\">Product Availability</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F141120\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F141119\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F141108\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F141123\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F141106\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F141177\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F141110\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F141126\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F141127\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F141128\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F141115\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F141105\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F141122\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F141129\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8696|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bezafibrate-united-states-not-available-patient-drug-information\" class=\"drug drug_patient\">Bezafibrate (United States: Not available): Patient drug information</a></li></ul></div></div>","javascript":null}